Pomerantz Law Firm Launches Investigation into Corcept Therapeutics Stock Claims

Pomerantz Law Firm Investigates Corcept Therapeutics Incorporated

The Pomerantz Law Firm, a leader in class action securities litigation, has announced an investigation into claims regarding Corcept Therapeutics Incorporated (NASDAQ: CORT). This inquiry comes on behalf of investors who may have suffered damages due to potential misconduct or fraud by the company and its executives.

Background of the Investigation

The investigation was initiated following a significant setback for Corcept Therapeutics. On December 31, 2025, the company released a statement indicating that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL). This letter pertained to the New Drug Application (NDA) for relacorilant, a treatment designed for patients suffering from hypertension due to hypercortisolism. The FDA acknowledged the success of Corcept's pivotal GRACE trial, confirming that it met its primary endpoint. However, they ultimately concluded that additional evidence of effectiveness would be required before a favorable benefit-risk assessment could be made.

Following this announcement, Corcept’s stock plummeted by an alarming $35.40 per share, equating to a decline of more than 50%, closing at $34.80 by the end of the trading day. This sharp decline raised serious concerns about whether the company and its leadership acted lawfully regarding shareholders’ interests.

Investigation Details

Investors affected by this stock price drop are encouraged to reach out to the Pomerantz Law Firm, particularly to attorney Danielle Peyton at [email protected] or via phone at 646-581-9980 ext. 7980. The firm aims to assess if there was any engagement in securities fraud or other unlawful business practices by Corcept and its management.

Pomerantz LLP, which has been at the forefront of securing justice for victims of corporate misconduct for over 85 years, has a rich history of recovering substantial damages for class members. Founded by Abraham L. Pomerantz, a revered figure in the legal domain of class actions, Pomerantz continues to uphold its legacy of fighting against securities fraud and breaches of fiduciary duty.

Implications for Investors

The existence of a CRL from the FDA raises multiple red flags for investors. It reveals a potential disconnect between the company's communicated efficacy of relacorilant and the FDA’s demand for more rigorous evidence. Such discrepancies can lead to questions regarding the transparency of corporate communications with investors. If investors believe they were misled about the prospects of relacorilant's approval, they may seek accountability through this ongoing legal investigation.

As the investigation unfolds, stakeholders in Corcept Therapeutics, whether currently invested or looking to gauge future risk, should stay informed about new developments. Understanding the outcomes of such legal inquiries can play a critical role in making well-informed investment decisions moving forward.

In closing, the Pomerantz Law Firm's investigation serves as a crucial reminder of the importance of corporate governance and ethical accountability. Investors who feel they have been affected by the fallout of this situation should take proactive steps to protect their interests, including engaging with professionals who specialize in securities law.

For additional updates or if you believe you have a case, please consult the provided outreach channels for assistance.